RevOpsis Therapeutics Secures $1.8M NEI SBIR Grant to Propel Innovative Ophthalmic Therapies
In a significant advancement for ophthalmic medicine, RevOpsis Therapeutics, a pioneering biopharmaceutical firm, has been awarded a Small Business Innovation Research (SBIR) grant exceeding $1.8 million from the National Eye Institute (NEI), part of the National Institutes of Health (NIH). This funding will bolster the development of their lead asset, RO-104, aimed at treating neovascular…